	US 12,285,472 B2
	Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
Liangfang Zhang, San Diego, CA (US); Che-Ming Jack Hu, San Diego, CA (US); Jonathan Copp, Cleveland, OH (US); Ronnie H. Fang, Irvine, CA (US); and Brian T. Luk, Irvine, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Appl. No. 15/505,148
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
PCT Filed Aug. 20, 2015, PCT No. PCT/US2015/046016 § 371(c)(1), (2) Date Feb. 20, 2017, PCT Pub. No. WO2016/028965, PCT Pub. Date Feb. 25, 2016.
Claims priority of provisional application 62/039,601, filed on Aug. 20, 2014.
Prior Publication US 2017/0274059 A1, Sep. 28, 2017
Int. Cl. A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 35/12 (2015.01); A61K 39/385 (2006.01); A61K 45/06 (2006.01); A61K 47/34 (2017.01)

CPC A61K 39/0008 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/5146 (2013.01); A61K 9/5184 (2013.01); A61K 35/12 (2013.01); A61K 39/385 (2013.01); A61K 45/06 (2013.01); A61K 47/34 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/6006 (2013.01)]

13 Claims

1. A method for reducing anemia symptoms in a subject, which method comprises:

administering, to a subject in need, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a plasma membrane isolated from a red blood cell (RBC) comprising a self-antigen that comprises glycophorin A and targets an anti-RBC autoantibody that causes anemia,

wherein said subject suffers from hemolytic anemia caused by opsonization of RBC with said anti-RBC auto-antibody, and said nanoparticle sequesters or neutralizes said anti-RBC autoantibody in said subject and reduces anemia symptoms in said subject.